Glaxosmithkline (GSK) Stock
Major global maker of medicines and vaccines. Here's the price, business snapshot, and what's worth knowing about Glaxosmithkline in October 2026.
GlaxoSmithKline PLC (GSK), listed as a sponsored ADR in the US under ticker GSK, is a large, diversified global healthcare company with a market capitalisation of roughly $89 billion. The business focuses on pharmaceuticals and vaccines after spinning off much of its consumer healthcare arm (Haleon) in recent years. Key investor considerations include R&D pipeline progress—particularly in respiratory, HIV and immunology areas—vaccine performance, regulatory approvals and patent expiries. GSK has a history of paying dividends, which may appeal to income-oriented investors, but dividend levels and the share price can fluctuate. Corporate strategy, partnerships and potential M&A are common catalysts. Risks include clinical trial setbacks, pricing and competition, currency and geopolitical exposure, and regulatory scrutiny. This summary is general educational information and not personal financial advice; investing involves risk, values can rise or fall, and past performance is not a reliable indicator. Consult a financial adviser for suitability.
Why It’s Moving
GSK Faces Earnings Headwinds Despite Hepatitis B Approval and Bone Cancer Data
- The US FDA approved GSK's hepatitis B treatment Hibsago (bepirovirsen), a move Jefferies notes supports a £2.2bn sales forecast and reinforces the company's pipeline strength.
- Experimental bone cancer drug data presented at a medical meeting showed delayed disease progression in patients, marking a key clinical win for GSK's partnership with Hansoh Pharmaceutical.
- Ahead of the October 28 earnings release, analysts warn of downside risks stemming from a $2.2 billion Zantac settlement charge and a looming patent cliff on GSK's top-selling HIV medicine.
GSK Faces Earnings Headwinds Despite Hepatitis B Approval and Bone Cancer Data
- The US FDA approved GSK's hepatitis B treatment Hibsago (bepirovirsen), a move Jefferies notes supports a £2.2bn sales forecast and reinforces the company's pipeline strength.
- Experimental bone cancer drug data presented at a medical meeting showed delayed disease progression in patients, marking a key clinical win for GSK's partnership with Hansoh Pharmaceutical.
- Ahead of the October 28 earnings release, analysts warn of downside risks stemming from a $2.2 billion Zantac settlement charge and a looming patent cliff on GSK's top-selling HIV medicine.
Sixth Month Growth Performance
When is the next earnings date for GlaxoSmithKline (GSK)?
GSK has not yet confirmed a specific date for its next earnings release. Based on the historical reporting pattern of approximately three months between reports, the upcoming announcement is expected in late January 2027. This report will cover the company's fourth quarter and full-year financial results for fiscal year 2026.
Stock Performance Snapshot
Analyst Rating
Analysts suggest buying GlaxoSmithKline's stock, anticipating it may rise in value soon.
Financial Health
GlaxoSmithKline is showing strong revenue and profit margins, indicating solid overall financial health.
Dividend
GlaxoSmithKline's projected dividend yield of 2.83% makes it a reasonable choice for dividend-seeking investors. If you invested $1000 you would be paid $28.30 a year in dividends (based on the last 12 months).
Why You’ll Want to Watch This Stock
Pipeline Catalysts
Late-stage trials and approvals can change growth prospects, though clinical setbacks are possible and can affect share value.
Vaccines & R&D
A strong vaccines franchise supports revenue potential, but R&D outcomes are uncertain and require close monitoring.
Global Reach & Risks
Exposure to international markets diversifies sales but brings currency, regulatory and geopolitical risks that can impact performance.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
